Goldman Sachs Maintains Buy on Grupo Cibest, Raises Price Target to $110
Goldman Sachs analyst Tito Labarta maintains Grupo Cibest (NYSE:CIB) with a Buy and raises the price target from $98 to $110.
Read original at benzingaStocks · News reference
Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also received an upgrade. See what analysts think.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Goldman Sachs analyst Tito Labarta maintains Grupo Cibest (NYSE:CIB) with a Buy and raises the price target from $98 to $110.
Read original at benzingaJP Morgan analyst Yuri Fernandes upgrades Grupo Cibest (NYSE:CIB) from Neutral to Overweight and raises the price target from $70 to $110.
Read original at benzingaGossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.
Read original at benzinga– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH –– Potential for Up to an Additional $100
Read original at benzinga